Biochemical Progression of Stage II High-Risk Multiple Myeloma
Biochemical Progression of Stage II High-Risk Multiple Myeloma
Biochemical Progression of Stage II Myeloma
July 2011
- A 61-year-old Caucasian female was diagnosed with stage II multiple myeloma
- Genetic testing showed t(14:16)
- At the time she was treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy followed by autologous stem cell transplantation
- She achieved a near complete remission with RVD and transplant
- Based on her high-risk cytogenetics, the patient was placed on lenalidomide maintenance therapy
August 2016
- On routine follow up, the patient reports having mild fatigue but continues to work full-time; she has grade 1 neuropathy
- M-protein, 1.3 g/dL
- SFLC, kappa, 150 mg/L
- Hb, 10.3 g/dL
- Creatinine, 1.3 mg/dL
Recent Videos
Related Content
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
November 25th 2024Article
The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported by DREAMM-7 and DREAMM-8 data.
Read More
